Navigation Links
Phase 1b/2a Program Commences for RVX-208
Date:8/25/2008

TSX Exchange Symbol: RVX

CALGARY, Aug. 25 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce that the Phase 1b/2a program for the study of RVX-208 in subjects with normal lipids and those with low high-density lipoprotein (HDL) cholesterol has proceeded according to plan.

"We are very excited about moving forward into this important 28-day study with RVX-208. Our previous clinical study demonstrated that RVX-208 was safe, tolerable and had favorable pharmacokinetics," stated Dr. Allan Gordon, Senior Vice President Clinical Development of Resverlogix. "This trial will continue to examine safety and tolerance as well it is a proof of principle study for ApoA-I production and HDL functionality. Approximately half of the subjects will have low levels of HDL cholesterol, a condition associated with significant increased risk of cardiovascular disease," added Dr. Gordon.

"The ensuing Phase 1b/2a study comprises several novel facets to expedite the clinical process for RVX-208 and its eventual registration as a drug," stated Donald J. McCaffrey, President and CEO of Resverlogix. McCaffrey further confirmed, "Along with the required regulatory provisions that must be addressed such as safety, tolerance and pharmacokinetics, the study also will measure key reverse cholesterol transport markers which RVX-208 impacts. These are exclusive favorable features that make this drug unique among its competitors."

RVX-208, a novel small molecule therapeutic that facilitates endogenous ApoA-I production, is positioned to be one of the most promising emerging drugs in the treatment of atherosclerosis. To the Company's knowledge RVX-208 is the only novel small molecule that is specifically designed to increase ApoA-I production and thereby raise HDL levels thus enhancing HDL functionality to augment reverse cholesterol transport.

About Resverlogix Corp.

Resverlogix Corp. is a leadin
'/>"/>

SOURCE Resverlogix Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Michigan Innovation Equipment Depot Launches Next Phase of Distribution
2. NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients
3. PTC124 Shows Promising Activity in Cystic Fibrosis; Phase 2 Proof-of-Concept Data Published in the Lancet
4. Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug
5. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
6. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
7. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
8. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
9. NOTICE OF YM BIOSCIENCES CONFERENCE CALL TO DISCUSS PHASE II DATA FOR NIMOTUZUMAB IN METASTATIC COLORECTAL CANCER
10. BioMS Medical completes patient recruitment in phase III U.S. multiple sclerosis trial
11. Nuvelo Initiates Phase 1 Clinical Trial of NU206 in Healthy Volunteers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... (PRWEB) September 30, 2014 Proove ... medicine, is excited to announce a new genetic test ... The Proove Pain Perception Test will provide physicians ... and why pain tolerance levels are stratified between individuals. ... identify whether a person has a genetic predisposition that ...
(Date:9/30/2014)... 30, 2014 Genedata, a ... drug discovery and related life science research, ... chosen Genedata Selector as its host-pathogen data ... FUNGITECT is a European consortium dedicated to ... via individualized anti-fungal drug therapies. Genedata Selector ...
(Date:9/30/2014)... MA (PRWEB) September 30, 2014 iLab ... Facility Management Benchmarking study which focuses on core ... common challenges core managers face today. , In its ... revealed. One of note is the year-over-year decrease in ... Core managers appear to be feeling the constraints of ...
(Date:9/30/2014)... Rainbow Scientific, Inc. (RSI), a ... opened an online store to add customer convenience ... developed and manufactured by Biological Industries, Inc. , ... Industries’ Nutristem® serum-free, xeno-free reagents for human mesenchymal ... (hESC) culture. , The online store also ...
Breaking Biology Technology:Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 2Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 3FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 2FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 3iLab Solutions Announces the Results of the 2014 Core Facility Benchmarking Study 2iLab Solutions Announces the Results of the 2014 Core Facility Benchmarking Study 3Rainbow Scientific, Inc. opens online store for state-of-the-art stem cell culture and cytogenetic reagents 2
... BERKELEY, Calif., Sept. 18 Dynavax,Technologies Corporation (Nasdaq: ... and Chief Financial Officer, will present an overview ... Sciences Conference in New York, New,York on Tuesday, ... Time,(6:30 a.m. PDST). The presentation will be webcast. ...
... Increasing Global Need for Genzyme Products, CAMBRIDGE, Mass., ... broke ground on a significant expansion of its,flagship manufacturing ... is focused on adding space for manufacturing support,functions, and ... The expansion was marked by a ceremony featuring Massachusetts ...
... Biopharmaceuticals Plc, a,private biopharmaceutical company focusing on ... it has,appointed Rosemary Mazanet M.D., Ph.D. as ... significant experience in both executive and,operational management ... serves on the Board of numerous private ...
Cached Biology Technology:Dynavax to Present at UBS 2007 Global Life Sciences Conference 2Genzyme Begins Major Expansion of Boston Manufacturing Facility 2Genzyme Begins Major Expansion of Boston Manufacturing Facility 3Genzyme Begins Major Expansion of Boston Manufacturing Facility 4Genzyme Begins Major Expansion of Boston Manufacturing Facility 5Morria Biopharmaceuticals Plc Announces Appointment of Dr. Rosemary Mazanet as Interim Chief Executive Officer 2
(Date:9/30/2014)... Researchers of Ludwig-Maximilians-Universitaet (LMU) in Munich report that ... cells more sensitive to chemotherapeutic drugs. They have ... a new target for anti-tumor agents. , ... Professor Stephan Sieber of the Technische Universitt Mnchen ... a potential new weapon in the fight against ...
(Date:9/30/2014)... threats in today,s ocean. From overfishing and pollution ... ecosystems are disappearing at unprecedented rates around the ... surrounding the island of Moorea in French Polynesia ... coral guard-crabs. New research from the National Museum ... McKeon and the museum,s predoctoral fellow Jenna Moore ...
(Date:9/29/2014)... Plants have a symbiotic relationship with certain bacteria. ... and defend against invaders an important step ... Now, scientist have discovered that plants may package ... that sprouting plants are colonized from the beginning. ... presented their findings today at the 5th ASM ...
Breaking Biology News(10 mins):Cancer therapy: Driving cancer cells to suicide 2Smithsonian scientists discover coral's best defender against an army of sea stars 2Plants prepackage beneficial microbes in their seeds 2
... at the University of Pennsylvania School of Medicine identified ... Epstein-Barr Virus (EBV) protein known to be expressed in ... new mechanism by which EBV can transform human B ... can lead to B-cell lymphomas. Now, they have found ...
... during development also control timing of aging and death, and ... researchers report in the journal Science. , "Although there ... there are genetic aspects to the processes of development and ... Molecular, Cellular and Developmental Biology and senior author of ...
... in the latest issue of Restoration Ecology finds that ... Oyster reefs are self-sustaining, and are additionally attractive ... long-term growth, and contribute to overall ecosystem stability and ... chemicals stimulate the oysters' settlement; reefs are therefore able ...
Cached Biology News:Mechanism for Epstein-Barr virus protein's role in blood cancers discovered 2MicroRNA gene that regulates lifespan found by Yale scientists 2
... Radiochemical Purity is >95%NEN Radiolabeled Ligands\n\nReceptor-related research ... availability of new radiolabeled ligands selected to ... a wide range of products and services ... over 400 state-of-the-art radioligands. If you do ...
... The Polymerase gene from Thermus ... expressed in E. coli, then highly ... It is used in the amplification ... PCR. The quality of the Taq ...
Request Info...
... iTaq DNA polymerase is ... suitable for both conventional and ... is supplied at a concentration ... and includes 250 units polymerase, ...
Biology Products: